NCT07594691 Inhale and Exhale Breath Holds to Improve the Radiation Therapy Accuracy in People With Upper Abdominal Cancers
| NCT ID | NCT07594691 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Abdominal Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2026-05-25 |
| Primary Completion | 2027-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2026-05-25 with a primary completion date of 2027-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective quality improvement study. The INEX RT P study will prospectively evaluate INEX RT R that optimizes radiation dose delivery to the target while minimizing dose to critical organs at risk (OAR) by treating patients with different phases of breath hold (inhale and exhale) during the same course of SBRT. 15 patients with abdominal cancer whom are expected to achieve a dosimetric advantage from this technique due to OAR proximity to target will be treated using INEX RT. Investigators hypothesize increasing the dose to the RT target by at least 10% while simultaneously decreasing or maintaining dose to adjacent critical OARs when using a combination of breath hold positions to purposefully vary the position of OARs during different fractions of the same treatment course, when compared to RT treatments planned on a single breath hold phase alone (present standard of care).
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 * Any patient undergoing radiation therapy for a cancer lesion in the abdomen in close proximity to OARs that is hypothesized to have differential displacement on inhale and exhale breath hold CT scans of the OAR relative to the tumor. * Patients need at least 3 fractions of RT * Critical OARs are within 2 cm of luminal GI structures, chest wall, or previous radiation fields * Able to receive and understand verbal and written information regarding study and able to give written informed consent Exclusion Criteria: * Inability to perform inhale or exhale breath holds during standard workflow CT simulation evaluation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07594691 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Abdominal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07594691 currently recruiting?
Yes, NCT07594691 is actively recruiting participants. Contact the research team at Laura.Dawson@uhn.ca for enrollment information.
Where is the NCT07594691 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT07594691 clinical trial?
NCT07594691 is sponsored by University Health Network, Toronto. The trial plans to enroll 15 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.